Technology

Our technology is based on the only available monoclonal antibody against a definable and extracellular linear target of the human calcitonin receptor (CTR). Accumulation of the CTR on the cell surface is an event associated with cell stress and Programmed Cell Death (PCD) – this is one of our key discoveries. The extracellular target epitope of our antibody makes it a suitable target for the delivery of therapeutic or diagnostic substances to reach diseased cells and tissues.

Our unique antibody enables the development of novel conjugates with applications in research and imaging, diagnostics and therapeutic interventions.

Products

Our first range of products are imaging reagents, conjugates of our proprietary antibody and a fluorophore for use with fluorescent imaging technologies, such as Confocal Laser Scanning Microscopy or Flow Cytometry. Please contact us if you want to receive a sample.

Publications

Furness SGB, Hare DL, Kourakis A, Turnley AM, Wookey PJ.  A novel ligand of calcitonin receptor reveals a potential new sensor that modulates programmed cell death. Cell Death Disc 2:16062; doi:10.1038/cddiscovery.2016.62, 2016. 

Gilabert-Oriol R, Furness SGB, Stringer BW, Weng A, Fuchs H, Day BW, Kourakis A, Boyd AW, Hare DL, Thakur M, Johns TG, Wookey PJ. Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high grade glioma cell lines derived from glioblastoma. Cancer Immunol Immunother 66:1217-1228, 2017. doi: 10.1007/s00262-017-2013-z.

Patents

PCT AU2008/001435. Diagnosis and treatment of diseased and damaged tissue. 

PCT AU2014/001081 (pending). Marker of cell death.

Pipeline

Apop Imaging is investing into an active research program toward the development of human therapeutic applications and non-invasive imaging tools to monitor cancer tumour tissues.